NCT06433219 2026-02-18
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
EMD Serono
Phase 2 Active not recruiting
EMD Serono
Memorial Sloan Kettering Cancer Center
Novartis
Revolution Medicines, Inc.
Faeth Therapeutics